HOME >> BIOLOGY >> NEWS
Enzymes Targeted As Key To Understanding Drug Interactions

You go to one doctor for your back problem. You see another for high blood pressure. Perhaps you consult a third for a nagging sinus infection. As part of your treatment, each writes a prescription or two. The result can be an array of pill bottles on your bathroom counter or breakfast table, perhaps augmenting your usual arsenal of over-the-counter supplements and pain and cold remedies.

How is the patient -- or the health care professional -- to know when the potential exists for a serious, even life-threatening, interaction between medications? Or when one drug may render another ineffective? News stories have highlighted the problem of pharmacists who failed to question prescriptions for dangerous drug combinations, and pharmacists complain of computer programs that fail to give them adequate warning of possible interactions.

A notorious example of a potentially deadly drug duo was Seldane, a popular antihistamine, and erithromycin, a common antibiotic, which when taken together could produce sometimes fatal heart problems. The U.S. Food and Drug Administration (FDA) has recommended that Seldane be withdrawn from the market.

Prevention of drug interactions, say researchers at the University of Washington School of Pharmacy, lies in learning how the human body processes each drug.

The school has recently established a formal Program in Drug Interactions, tapping the expertise of 22 faculty members believed to be the largest group of experts in the world on drug interactions.

The UW investigators are seeking systematic knowledge of how various enzymes -- biochemical catalysts produced by the body -- metabolize drugs. Their research is producing an understanding of the potential for adverse effects among thousands of drug combinations.

"Pharmacists have had to remember hundreds of pairs of drugs that interact," said the program's director, Dr. Rene Levy, professor and chair of pharmaceutics. "But there was a shift in our knowedge
'"/>

Contact: Laurie McHale
lmchale@u.washington.edu
206-543-3620
University of Washington
28-May-1997


Page: 1 2

Related biology news :

1. Constructing "Designer" Plant Enzymes
2. Engineering New Enzymes
3. Spinach Enzymes Neutralize Explosives
4. Worm Wizardry: Worlds Most Heat-Tolerant Creature Suggests Enzymes For Drugs OrIndustry, UD Prof Says
5. Targeted therapy knocks out pediatric brain cancer in mice
6. Targeted therapy for lung cancer patients shows promise in extending lives
7. Targeted immunotherapy eradicates cancer in mice
8. Targeted radiation to liver tumors spares tissue, improves quality of life
9. Targeted Genetics presents data on arthritis gene therapy
10. Targeted genetics presents promising data from cystic fibrosis clinical trial
11. Targeted Genetics presents clinical data on E1A cancer gene therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
Cached News: